Factors associated to first line antiretroviral therapy (ART) failure among HIV/AIDS patients at Sanglah Hospital, Bali
DOI:
https://doi.org/10.53638/phpma.2017.v5.i1.p02Keywords:
treatment failure, first-line ART, HIV/AIDS, BaliAbstract
Background and purpose: The incidence of first line ART failure is increasing in the South East Asia region. The main referral hospital in Bali has recorded an increased use of second line ART due to the first line ART failure. This study aims to explore risk factors associated to first line ART failure.
Methods: A case control study was conducted among people living with HIV and AIDS at Sanglah Hospital Denpasar who started first line ART between 2004 and 2013. Cases were those who diagnosed as having clinical treatment failure and still on treatment in 2015. Controls were those with no treatment failure. Sex and year of ART initiation were matched between case and control. Data were obtained from medical records that include initial regiments, HIV mode of transmission, the WHO HIV clinical stage, CD4 count, opportunistic infections, body mass index, hemoglobin level, and drug substitution at the beginning and during treatment. Risk factors were analysed using logistic regression.
Results: Out of 68 HIV/AIDS patients with clinical ART failure, 72.1% were confirmed with immunological and 36.8% were confirmed with virological failure. Median time before treatment failure was 3.5 years. Factors associated to ART failure were HIV clinical stage IV (AOR=3.43; 95%CI: 1.65-7.13) and being widow/widower (AOR=4.85; 95%CI: 1.52-15.53). Patients with TB co-infection have a lower risk for treatment failure due to early diagnosis and treatment through TB-HIV program (AOR=0.32; 95%CI: 0.14-0.70).
Conclusions: Higher HIV clinical stage at ART initiation increases the risk of treatment failure. HIV-TB co-infection indirectly reduces the risk of treatment failure.
References
Ministry of Health of Indonesia. Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral pada Orang Dewasa [National Guideline on Clinical Management of HIV Infection and ART for Adult]. Jakarta: Kementerian Kesehatan RI; 2011.
WHO-HIV Treatment. Global Update on HIV Treatment 2013; Result, Impact and Opportunities. Geneva Switzerland: Publications of the World Health Organization; 2013.
WHO-Technical Report. Antiretroviral Medicines in Low and Middle Income Countries: Forecasts of Global and Regional Demand for 2014-2018. Geneva Switzerland: Publications of the World Health Organization; 2015.
Duong AT, Kato M, Bales. Costing Analysis of National HIV Treatment and Care Program in Vietnam. J Acquir Immune Defic Syndr; 2014; 65: 1-7.
Long L, Fox M, Sannea I, Rosena S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa; 2010; 24: 915–919.
Castelnuovo B, John LD, Lutwama F, Ronald A, Spacek LA, Bates M, Kamya MR, Colebunders R. Three-Year Outcome Data of Second-Line Antiretroviral Therapy in Ugandan Adults: Good Virological Response but High Rate of Toxicity. Journal of the International Association of Physicians in AIDS Care; 2009; 8: 52-59.
Yuniar Y, Syaripuddin M, Isakh BM, 2014. Manajemen Logistik Obat Antiretroviral di Indonesia [Logistic Management of Antiretroviral in Indonesia]. Buletin Penelitian Sistem Kesehatan; 2011; 17: 125–134.
WHO-HIV/AIDS Media Center. Key Facts HIV/AIDS. Geneva Switzerland: Publications of the World Health Organization; 2015.
Madec Y, Leroy S, Cuille MAR, Huber F, Calmy A. Persistent Difficulties in Switching to Second-Line ART in Sub-Saharan Africa — A Systematic Review and Meta-Analysis. PLoS One; 2014; 9(4): e95820.
Trotter AB, Hong SY, Srikantiah P, Abeyewickreme I, Bertagnolio S, Jordan MR. Systematic Review of HIV Drug Resistance in the World Health Organization Southeast Asia Region. AIDS Rev; 2013; 15 (3): 162-170.
Subuh M. Laporan Perkembangan HIV-AIDS Triwulan I Tahun 2015 [HIV/AIDS Update Report First Trimester 2015]. Surat Edaran pada Pertemuan Monitoring dan Evaluasi Nasional HIV-AIDS Tengah Semester 2015. Jakarta 8-12 Juni; 2015.
Fox MP, Van Cutsem G, Giddy J, Maskew M, Keiser O, Prozesky H, Wood R, Hernan MA, Sterne JAC, Egger M, Boulle A. 2009. Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa. J Acquir Immune DeficSyndr; 2012;60(4): 428–437.
Chandya S, Singha G, Heylenb E, Gandhic M, Ekstrand ML. Treatment switching in South Indian patients on HAART: What are the predictors and consequences. AIDS Care; 2011; 23(5): 569–577.
Palombi L, Marazzi MC, Guidotti G, Germano P, Buonomo E, Scarcella P, Altan AD, Zimba IDVM, Lio MMS, Luca AD. Incidence and Predictors of Death, Retention, and Switch to Second-Line Regimens in Antiretroviral-Treated Patients in Sub-Saharan African Sites with Comprehensive Monitoring Availability. Clinical Infectious Diseases-Oxford University; 2009; 48(1): 115-122
Abah IO, Darin KM, Ebonyi AO, Ugoagwu P, Ojeh VB, Nasir N, Falang KD, Olaitan O, Agbaji O, Idoko J, Kanki P. Patterns and Predictors of First-Line Antiretroviral Therapy Modification in HIV-1-Infected Adults in a Large Urban Outpatient Cohort in Nigeria, Journal of the International Association of Providers of AIDS Care; 2015; 14(4) : 348-354.
Hawkins C, Achenbach C, Fryda W, Ngare D, Murphy R. Antiretroviral Durability and Tolerability in HIV-Infected Adults Living in Urban Kenya. J Acquir Immune DeficSyndr; 2007; 45: 304–310.
Penot P, Hema A, Bado G, Kabore F, Sore I, Sombie D, Traore JR, Schmid JBG, Fontanet A, Slama L, Sawadogo AB, Laurent C. The vulnerability of men to virologic failure during antiretroviral therapy in a public routine clinic in Burkina Faso. Journal of the International AIDS Society; 2014, 17:18646.
Jiamsakul A, Sungkanuparph S, Law M, Kantor R, Praparattanapan J, Li PCK., Phanuphak P, Merati T, Ratanasuwan W, Lee CKC, Ditangco R, Mustafa M, Singtoroj T, Kiertiburanakul S. HIV Multidrug Resistance at First Line Antiretroviral Failure and Subsequent VirologicalRespone in Asia. Journal of the International AIDS Society; 2014, 17:19053-19063.
Robbins GK, Daniels B, Zheng H, Chueh H, Meigs JB, Freedberg KA. Predictors of Antiretroviral Treatment Failure in an Urban HIV Clinic. J Acquir Immune Defic Syndr; 2007; 44 (1): 30-37.
Fibriani A, Wisaksana R, Indrati A, Hartantri Y, Vijver D, Schutten M, Alisjahbana B, Sudjana P, Boucher CAB., Crevel R, Ven A. Virological Failure and Drug Resistance during First Line Anti-Retroviral Treatment in Indonesia. J. Med. Virol; 2013; 85:1394–1401.
Beaudrap PD, Thiam M, Diouf A, Toure-Kane C, Ngom-Guèye NF, Vidal N, Mboup S, Ndoye I, Sow PS, Delaporte E. Risk of Virological Failure and Drug Resistance during First and Second-Line Antiretroviral Therapy in a 10-Year Cohort in Senegal: Results From the ANRS 1215 Cohort. J Acquir Immune DeficSynd; 2013; 62: 381–387.
Vanobberghen FM, Kilama B, Wringe A, Ramadhani A, Zaba B, Mmbando D, Todd J. Immunological failure of first-line and switch to second-line antiretroviral therapy among HIV-infected persons in Tanzania: analysis of routinely collected national data. Tropical Medicine and International Health; 2015; 20 (7): 880–892.
Charles M, Leger PD, Severe P, Guiteau C, Apollon A, Gulick RM, Johnson WD, Pape JW, Fitzgerald DW. Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti. Journal of the International AIDS Society; 2011; 15:17375
Gras G, Schneider MP, Cavassini M, Lucht F, Loilier M, Verdon R, Bernard L, Parienti JJ. Patterns of Adherence to Raltegravir-Based Regimens and the Risk of Virological Failure among HIV-Infected Patients: The RALTECAPS Cohort Study. J Acquir Immune DeficSyndr; 2012; 61 (3): 265-269.
Jespersen S, Hønge BL, Medina C, Te DS, Correira FG, Laursen AL, Erikstrup C, Østergaard L, Wejse C. Lack of awareness of treatment failure among HIV-1-infected patients in Guinea-Bissau-a retrospective cohort study. Journal of the International AIDS Society; 2015; 18:20243.
Leng X, Liang S, Ma Y, Dong Y, Kan W, Goan D, Hsi JH, Liao L, Wang J, He C, Zhang H, Xing H, Ruan Y, Shao Y. HIV virological failure and drug resistance among injecting drug users receiving first-line ART in China. BMJ Open; 2014; 4: e005886.
Caseiro MM, Golegã AAC, Etzel A, Diaz RS. Characterization of Virologic Failure After an Initially Successful 48-Week Course of Antiretroviral Therapy in HIV/AIDS Outpatients Treated in Santos, Brazil. The Brazilian Journal of Infectious Disease; 2008; 12(3):162-166.
Lynen L, An S, Koole O, Thai S, Ros S, Munter P, Sculier D, Arnould L, Fransen K, Menten J, Boelaert M, Ende J, Colebunders R. 2008. An Algorithm to Optimize Viral Load Testing in HIV-Positive Patients with Suspected First-Line Antiretroviral Therapy Failure in Cambodia. J Acquir Immune DeficSyndr 2009; 52: 40–48.
Bali Provincial Health Office. Profil Dinas Kesehatan Provinsi Bali. [Profile of Bali Provincial Health Office]. Denpasar. Dinas Kesehatan Provinsi Bali; 2015.
Utama MS, Merati TP. Association of Opportunistic Infections with HIV RNA and CD4 Cell Count in Pre ARV and ARV Failure at The Care Support Treatment Clinic of Sanglah Hospital Bali. Journal of Epidemiological Research; 2016; 2 (2): 13-17.
Ghate M, Deshpande S, Tripathy S, Nene M, Gedam P, Godbole S, Thakar M, Risbud A, Bollinger R, Mehendale S. Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: analysis by stages of immunosuppression represented by CD4 counts. International Journal of Infectious Diseases; 2009; 13: 1-8
Parto DN, Budhi A, Arifin N. 2008. Factors Associated to Success Tuberculosis Therapy of Co-infection TB-HIV Patients in Persahabatan Hospital, Jakarta-Indonesia. J Respir Indo; 2011; 31 (1).
Neel GR, Moll AP, Lalloo U, Pawinski R, Zeller K, Moodley P, Meyer E, Friedland G. Successful Integration of Tuberculosis and HIV Treatment in Rural South Africa. J Acquir Immune DeficSyndr; 2009;50:37–43
Owiti P, Zachariah R, Bissel K, Kumar AMV, Diero L, Carter EJ, Gardner A. 2012. Integrating Tuberculosis and HIV Services in Rural Kenya, Uptake and Outcomes. Public Health Action; 2015; 5(1): 36–44
Caseiro MM, Golegã AAC, Etzel A, Diaz RS. Characterization of Virologic Failure After an Initially Successful 48-Week Course of Antiretroviral Therapy in HIV/AIDS Outpatients Treated in Santos, Brazil. The Brazilian Journal of Infectious Diseases; 2008; 12 (3):162-166.
Sungkanuparph S, Groger RK, Overton ET, Fraser VJ, Powderly WG. 2006. Persistent Low Level Viraemia and Virological Failure in HIV-1 Infected Patients Treated with Highly Active Antiretroviral Therapy. HIV Medicine; 2006; 7: 437–441.
Ma Y, Zhao D, Yu L, Bulterys M, Robinson ML, Zhao Y, Dou Z, Chiliade Z, Wei X, Zhang F. Predictors of virologic failure in HIV-1-infected adults on first line antiretroviral therapy in eight provinces in China. Clinical Infectious Diseases; 2009; 50 : 264-271
Romanee C, Charussri W, Wilai K, Jutharat P, Thira S, Khuanchai S. Sensitivity and Specificity of Using CD4 Measurement and Clinical Evaluation to Determine Antiretroviral Treatment Failure in Thailand. International Journal of Infectious Diseases; 2007; 11: 413—416.
Gsponera T, Petersenb M, Eggera M, Phirid S, Maathuise MH, Boullec A, Musondadf P, Tweyad H, Petere K, Chig BH, Keisera O. The Causal Effect of Switching to Second–line ART in Programmes without Access to Routine Viral Load Monitoring. AIDS; 201; 26(1): 57–65.
Gilks CF, Walker AS, Munderi P, Kityo C, Reid A, Katabira E, et al. A Single CD4 Test with 250 cells/mm3 Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria. Published: Feb 21, 2013 http://dx.doi.org/10.1371/journal.pone.0057580
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Cok Istri Sri Dharma Astiti, Anak Agung Sagung Sawitri, Ketut Tuti Parwati Merati
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
**Creative Commons Attribution 4.0 International License (CC BY 4.0)**
*Welcome to the world of open collaboration and shared creativity! The Creative Commons Attribution 4.0 International License (CC BY 4.0) empowers creators to share their work with the world while maintaining certain rights.*
**Key Points:**
1. **Freedom to Share:** CC BY 4.0 allows creators to share their work globally, granting others the freedom to use, remix, and build upon it.
2. **Attribution Requirement:** Users can use the work for any purpose, even commercially, as long as they provide appropriate credit to the original creator.
3. **Flexibility:** Applicable to various content types—text, images, music, videos—the license fosters a diverse range of creations.
**Common Use Cases:**
- **Education:** Widely used for educational materials, promoting open learning environments.
- **Research:** Applied to scholarly articles, accelerating the dissemination of knowledge.
**How to Use:**
1. **Share:** Share your work with the world, marking it with the CC BY 4.0 license.
2. **Attribution:** Users, when utilizing the work, must provide proper attribution to honor the original creator.
**Conclusion:**
CC BY 4.0 contributes to a more open and collaborative digital landscape. Join the movement of shared knowledge and creativity!
*For full license details, visit [Creative Commons](https://creativecommons.org/licenses/by/4.0/).*
